APRESOLINE Drug Patent Profile

When do Apresoline patents expire, and when can generic versions of Apresoline launch?

Apresoline is a drug marketed by Novartis and is included in two NDAs.

The generic ingredient in APRESOLINE is hydralazine hydrochloride; hydrochlorothiazide. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide profile page.

Summary for APRESOLINE

US Patents:	0
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for APRESOLINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	APRESOLINE	hydralazine hydrochloride	INJECTABLE;INJECTION	008303-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Novartis	APRESOLINE	hydralazine hydrochloride	TABLET;ORAL	008303-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Novartis	APRESOLINE	hydralazine hydrochloride	TABLET;ORAL	008303-004	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Novartis	APRESOLINE	hydralazine hydrochloride	TABLET;ORAL	008303-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Novartis	APRESOLINE-ESIDRIX	hydralazine hydrochloride; hydrochlorothiazide	TABLET;ORAL	012026-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Novartis	APRESOLINE	hydralazine hydrochloride	TABLET;ORAL	008303-005	Approved Prior to Jan 1, 1982		DISCN	Yes	No

APRESOLINE (Hydralazine Hydrochloride): Investment Fundamentals and Patent Landscape Analysis

Last updated: February 19, 2026

This report analyzes the investment landscape and patent fundamentals for APRESOLINE (hydralazine hydrochloride), a vasodilator primarily used to treat hypertension. The analysis focuses on its current market position, patent expiry, and potential for future development or acquisition, providing data for R&D and investment decisions.

What Is APRESOLINE?

APRESOLINE, the brand name for hydralazine hydrochloride, is an antihypertensive agent. It functions as a direct-acting peripheral vasodilator, causing relaxation of vascular smooth muscle, which leads to a decrease in blood pressure. Its primary indication is for the management of essential hypertension and hypertensive emergencies. It is also used in combination with other antihypertensive agents.

The mechanism of action involves inhibiting the influx of extracellular calcium ions into vascular smooth muscle and the intracellular storage of calcium. It may also interfere with the intracellular release of calcium from the sarcoplasmic reticulum. Hydralazine is rapidly absorbed from the gastrointestinal tract, with bioavailability approximately 20-30% due to significant first-pass metabolism. It is metabolized primarily in the liver through acetylation and conjugation pathways.

Key Characteristics of APRESOLINE:

• Chemical Name: 1-hydrazinophthalazine hydrochloride
• Therapeutic Class: Antihypertensive, Vasodilator
• Primary Indication: Essential hypertension, hypertensive emergencies
• Mechanism of Action: Direct peripheral vasodilator
• Route of Administration: Oral, Intravenous (IV)
• Onset of Action: Oral: 20-30 minutes; IV: 5-20 minutes
• Duration of Action: Oral: 2-6 hours; IV: 2-4 hours
• Common Side Effects: Headache, dizziness, tachycardia, nausea, flushing

APRESOLINE was first synthesized in the 1940s and approved by the U.S. Food and Drug Administration (FDA) in 1954. Its long history has established it as a well-understood medication with a known efficacy and safety profile, although it is often reserved for specific patient populations or situations due to potential side effects and the availability of newer antihypertensive classes.

What Is the Current Market Position of APRESOLINE?

APRESOLINE is available as a generic medication, with its primary active pharmaceutical ingredient (API) being hydralazine hydrochloride. The market is characterized by multiple generic manufacturers, leading to competitive pricing. The drug's established efficacy and low cost contribute to its continued use, particularly in certain healthcare systems and for specific indications where other agents are less suitable or more expensive.

Market Drivers:

• Cost-Effectiveness: As a generic drug, hydralazine hydrochloride offers a lower price point compared to many branded or newer antihypertensive medications. This is a significant factor in institutional settings and for patients with limited financial resources.
• Established Efficacy: The drug has a long track record of efficacy in lowering blood pressure, particularly in moderate to severe hypertension and hypertensive emergencies.
• Specific Indications: It remains a component of treatment guidelines for certain conditions, such as pre-eclampsia and eclampsia, in pregnant women, where its safety and efficacy are well-documented. It is also used in combination therapy and for patients resistant to other treatments.
• Oral and IV Formulations: The availability of both oral and intravenous formulations allows for flexible treatment approaches, from chronic management to acute hypertensive crises.

Market Challenges:

• Availability of Newer Drug Classes: The development of newer antihypertensive drug classes (e.g., ACE inhibitors, ARBs, calcium channel blockers, beta-blockers, diuretics) with generally better side effect profiles and more convenient dosing regimens has reduced the first-line use of hydralazine hydrochloride for many patients with essential hypertension.
• Side Effect Profile: Common side effects such as headache, reflex tachycardia, and fluid retention, along with the potential for drug-induced lupus erythematosus and peripheral neuropathy with long-term use, can limit its appeal for routine management.
• Generic Competition: The presence of numerous generic manufacturers intensifies price competition, potentially limiting profit margins for any single company producing hydralazine hydrochloride.
• Limited Innovation: As an older drug, there is limited scope for significant new clinical development or patentable innovation related to the API itself.

Key Manufacturers/Suppliers:

While specific market share data for individual generic manufacturers of hydralazine hydrochloride is not publicly available due to the nature of the generic market, prominent suppliers in the U.S. include companies such as:

• Endo Pharmaceuticals (via Qualitest Pharmaceuticals): Has historically been a significant supplier.
• Teva Pharmaceuticals: A major global generic drug manufacturer.
• Amneal Pharmaceuticals: Another significant player in the U.S. generic market.
• Generic Health Companies: Numerous other smaller and regional generic manufacturers.

The market is largely driven by supply agreements with wholesalers, distributors, and hospital pharmacies, rather than direct-to-consumer marketing.

What Is the Patent Landscape for APRESOLINE?

APRESOLINE (hydralazine hydrochloride) is a drug whose original composition of matter patents expired decades ago. Consequently, there are no active, unexpired patents covering the basic molecule or its primary uses. This lack of patent protection means that the market is fully open to generic competition.

Historical Patent Expiry:

• Original Composition of Matter Patents: The foundational patents for hydralazine hydrochloride were filed and expired in the mid-20th century. Specific patent numbers and their expiry dates are difficult to pinpoint due to the age and the historical patent system, but they would have expired well before the year 2000.
• Formulation and Manufacturing Patents: Over the years, there may have been patents filed for specific manufacturing processes, improved formulations (e.g., extended-release versions, specific salt forms, or combination products), or novel delivery systems. However, the vast majority of these would also have expired.

Current Patent Status:

• No Active Composition of Matter Patents: There are no active patents preventing the manufacture or sale of generic hydralazine hydrochloride.
• Limited Potential for New Patents: While it is theoretically possible to patent novel and non-obvious uses, formulations, or manufacturing methods, the historical data and extensive clinical use of hydralazine make the bar for achieving patentability very high. Any new patents would likely be very narrow and specific. For example, a patent might exist for a specific, proprietary manufacturing process that offers significant cost or purity advantages, but this would not prevent others from using alternative, unpatented manufacturing methods.

Implications for Investment:

The absence of patent protection means that the investment thesis for APRESOLINE does not rely on exclusivity periods or market monopolies driven by intellectual property. Investment in companies manufacturing generic hydralazine hydrochloride would be based on:

• Manufacturing Efficiency: Ability to produce the API and finished dosage forms at a competitive cost.
• Supply Chain Management: Reliable sourcing of raw materials and efficient distribution.
• Regulatory Compliance: Adherence to FDA (and other regulatory bodies') Good Manufacturing Practices (GMP).
• Market Volume: Capturing a share of the demand for this established generic medication.

Any investment scenario involving APRESOLINE is therefore situated within the generic pharmaceuticals market, where competition, cost of goods sold, and market access are primary drivers of profitability, rather than the innovation-driven exclusivity typically associated with novel drug development.

What Are the Regulatory Considerations for APRESOLINE?

APRESOLINE, as a prescription drug with a long history of approval, is subject to ongoing regulatory oversight by the U.S. Food and Drug Administration (FDA) and equivalent bodies globally. The primary regulatory considerations revolve around manufacturing, quality control, labeling, and post-market surveillance.

Key Regulatory Areas:

• Drug Master Files (DMFs) and Abbreviated New Drug Applications (ANDAs): Manufacturers of generic hydralazine hydrochloride must file ANDAs with the FDA. These applications demonstrate that the generic product is bioequivalent to the reference listed drug (RLD) and meets all quality and manufacturing standards. The API itself is typically supported by a Drug Master File (DMF), which contains detailed information about the manufacturing process, facilities, and controls.
• Current Good Manufacturing Practices (cGMP): All facilities involved in the manufacturing of hydralazine hydrochloride, from API synthesis to finished product formulation, must comply with cGMP regulations. FDA inspections are conducted periodically to ensure ongoing compliance. Deviations can lead to warning letters, import alerts, or product recalls.
• Labeling and Prescribing Information: Prescribing information must accurately reflect the current understanding of the drug's efficacy, safety, dosage, administration, contraindications, warnings, precautions, and adverse reactions. Manufacturers are responsible for updating labeling as new safety information emerges.
• Post-Market Surveillance and Pharmacovigilance: Companies are required to monitor and report adverse events associated with their products. This includes spontaneous reporting of adverse drug reactions (ADRs) to regulatory authorities.
• Quality Control and Testing: Rigorous quality control testing is essential at all stages of manufacturing to ensure the identity, strength, quality, and purity of the drug product. This includes testing for impurities, dissolution, and stability.
• Supply Chain Integrity: Ensuring the integrity of the supply chain is critical to prevent counterfeiting and ensure product quality. This involves secure sourcing of raw materials and robust distribution controls.

Specific Regulatory Status:

• FDA Approval: Hydralazine hydrochloride is an FDA-approved drug.
• Orphan Drug Status: Hydralazine hydrochloride does not have orphan drug designation in the U.S. for its primary indications, meaning it is not eligible for the market exclusivity associated with rare disease treatments.
• Pediatric Use: While hydralazine may be used in pediatric patients, specific pediatric studies leading to full FDA approval for all pediatric age groups may be limited. Off-label use in pediatrics is common, guided by clinical judgment and available literature.
• Pregnancy Categories: Hydralazine is classified under FDA pregnancy categories, typically Category C (risk cannot be ruled out) for general use, but it is a preferred agent for treating severe hypertension in pregnancy, including pre-eclampsia.

For investment or R&D, regulatory compliance is a fundamental prerequisite for any company involved with APRESOLINE. Any significant regulatory action against a manufacturer could severely impact its ability to market the product and affect its financial performance.

What Are the Potential Future Developments or Investment Scenarios for APRESOLINE?

Given that APRESOLINE (hydralazine hydrochloride) is a mature, generic drug with no active patent protection, investment and development scenarios are limited to optimizing its existing market position or exploring niche applications. The absence of patent exclusivity means that significant R&D investment in novel formulations or mechanisms of action for the core API is unlikely to yield patent-protected market advantages.

Potential Investment & Development Scenarios:

1. Manufacturing Optimization and Cost Reduction:

   • Focus: Companies with highly efficient manufacturing processes and robust supply chains can achieve competitive pricing. Investment in process improvements, automation, and strategic raw material sourcing can lead to better margins in a price-sensitive generic market.
   • Investment Rationale: Capturing market share through cost leadership. This is a strategy for established generic manufacturers.
   • Example: A company investing in a new synthesis route for hydralazine API that significantly reduces the cost of goods sold.

2. Niche or Orphan Indications:

   • Focus: While hydralazine is primarily known for hypertension, it has been explored or used off-label in other areas. Identifying and pursuing regulatory approval for a specific, underserved niche indication could potentially lead to a period of market exclusivity if granted orphan drug status or a new indication exclusivity (though the latter is less common for older drugs).
   • Investment Rationale: Creating a new, potentially patent-protected market segment for an otherwise generic molecule. This would involve significant clinical trial investment.
   • Example: Hypothetically, if new research identified hydralazine as highly effective for a specific rare cardiovascular condition, a company might pursue clinical trials and seek FDA approval for this new indication. However, the historical data might limit the "novelty" required for strong patent claims around the new use.

3. Combination Therapies:

   • Focus: Developing fixed-dose combination products that pair hydralazine with another antihypertensive agent. While existing combination therapies exist, there might be opportunities for novel combinations addressing specific unmet needs or improving patient adherence.
   • Investment Rationale: Offering an improved therapeutic regimen or enhanced patient convenience. New combination products can achieve some degree of market differentiation, even without composition of matter patents on individual components. Patentability might lie in the specific ratios, synergistic effects, or unique delivery mechanisms of the combination.
   • Example: A fixed-dose combination tablet of hydralazine with a novel diuretic or beta-blocker with a differentiated profile.

4. Extended-Release Formulations (Limited Potential):

   • Focus: Historically, extended-release (ER) formulations have been patented to improve dosing convenience and reduce peak-trough fluctuations of drugs. While ER hydralazine products may exist or have existed, the patent landscape for such formulations would likely have expired or be close to expiry. However, a truly novel ER technology applied to hydralazine could, in theory, be patentable.
   • Investment Rationale: Improving patient compliance and therapeutic profile. This would require substantial formulation development.
   • Example: A sustained-release formulation that provides 24-hour blood pressure control with once-daily dosing.

5. Acquisition of Existing Generic Manufacturing Assets:

   • Focus: Private equity or larger pharmaceutical companies might acquire established generic manufacturers that produce hydralazine hydrochloride, along with other portfolio products. The acquisition would be based on the revenue stream from these mature products and the manufacturing capacity.
   • Investment Rationale: Consolidating market position, achieving economies of scale, and diversifying revenue from established generics.
   • Example: A large generic pharmaceutical company acquiring a smaller competitor to increase its overall market share in cardiovascular generics.

Key Considerations for Future Investment:

• Limited Innovation Potential: The core API has limited potential for novel discovery.
• Cost of Clinical Development: Pursuing new indications or advanced formulations requires significant investment in clinical trials, which may be difficult to recoup given the drug's generic pricing.
• Regulatory Hurdles: Obtaining approval for new indications or complex formulations involves lengthy regulatory processes.
• Competitive Landscape: The generic market is highly competitive, with pressure on pricing.

Any future development involving APRESOLINE will likely focus on operational excellence, strategic market positioning within the generic space, or highly specific niche applications where a regulatory or clinical advantage can be established.

---

Key Takeaways

• APRESOLINE (hydralazine hydrochloride) is a mature, generic antihypertensive drug with no active composition of matter patents.
• Its market position is driven by cost-effectiveness and established efficacy, particularly in specific patient populations (e.g., pregnant women) and as a second or third-line agent.
• The drug faces competition from newer antihypertensive classes with more favorable side effect profiles and convenience.
• Regulatory compliance, manufacturing efficiency, and supply chain integrity are critical for companies involved in APRESOLINE production.
• Future investment scenarios are limited to manufacturing optimization, niche indication pursuit (challenging due to lack of patentability), combination therapies, or acquisition of existing generic assets.

---

Frequently Asked Questions

1. What is the primary competitive advantage for a generic manufacturer of APRESOLINE? The primary competitive advantage lies in manufacturing efficiency and cost leadership, enabling competitive pricing in a market driven by generics.

2. Are there any ongoing clinical trials investigating new uses for hydralazine hydrochloride? Publicly available databases (e.g., ClinicalTrials.gov) do not currently list significant ongoing trials for novel indications of hydralazine hydrochloride beyond its established uses in hypertension.

3. What is the typical profit margin for a generic drug like APRESOLINE? Profit margins for generic drugs vary significantly based on manufacturing costs, market competition, and sales volume. However, margins on established generics are generally lower than for patented novel drugs, necessitating high sales volumes to achieve substantial profits.

4. Can a company patent a new manufacturing process for hydralazine hydrochloride? Yes, a company can potentially patent a novel, non-obvious, and industrially applicable manufacturing process for hydralazine hydrochloride, provided it offers significant improvements (e.g., higher purity, lower cost, reduced environmental impact). This patent would cover the specific process, not the drug itself.

5. What is the risk of a recall for APRESOLINE due to quality issues? The risk of recall exists for any pharmaceutical product, including APRESOLINE. Such events are typically triggered by detected manufacturing defects, impurity issues, or stability problems that violate cGMP standards and compromise product safety or efficacy.

---

Citations

[1] U.S. Food & Drug Administration. (n.d.). ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/ [2] U.S. Food & Drug Administration. (n.d.). Guidance for Industry. U.S. Department of Health and Human Services. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidance-industry